{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/ELVN/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-08T14:15:37.108Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":6771,"canonical_name":"Enliven Therapeutics, Inc.","cik":"0001672619","uei":null,"lei":null,"duns":null,"ticker":"ELVN"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":85},"count":85,"timeline":[{"ts":"2026-07-21","kind":"sec.filing","form_type":"4","title":"4 — Enliven Therapeutics, Inc. — 2026-07-21","url_slug":"/sec/cik-0001672619/4/0001701247-26-000011","accession_number":"0001701247-26-000011","importance":30},{"ts":"2026-07-21","kind":"sec.filing","form_type":"4","title":"4 — Enliven Therapeutics, Inc. — 2026-07-21","url_slug":"/sec/cik-0001672619/4/0001882764-26-000006","accession_number":"0001882764-26-000006","importance":30},{"ts":"2026-07-17","kind":"sec.form144","reporter":"Collins Helen Louise","title":"Officer","shares":15000,"usd_value":762900,"security_title":"Common","approx_sale_date":"2026-07-17","accession_number":"0001974158-26-000084","importance":40.15258},{"ts":"2026-07-17","kind":"sec.insider.s","reporter":"Hohl Benjamin","title":"CHIEF FINANCIAL OFFICER","shares":2638,"price_per_share":53.3825,"usd_value":140823,"security_title":"Common Stock","importance":35.140823035},{"ts":"2026-07-17","kind":"sec.insider.s","reporter":"Hohl Benjamin","title":"CHIEF FINANCIAL OFFICER","shares":2564,"price_per_share":52.318,"usd_value":134143,"security_title":"Common Stock","importance":35.134143352},{"ts":"2026-07-17","kind":"sec.insider.s","reporter":"Collins Helen Louise","title":"CHIEF MEDICAL OFFICER","shares":2184,"price_per_share":53.4199,"usd_value":116669,"security_title":"Common Stock","importance":35.1166690616},{"ts":"2026-07-17","kind":"sec.insider.s","reporter":"Collins Helen Louise","title":"CHIEF MEDICAL OFFICER","shares":2063,"price_per_share":52.3921,"usd_value":108085,"security_title":"Common Stock","importance":35.1080849023},{"ts":"2026-07-17","kind":"sec.insider.s","reporter":"Collins Helen Louise","title":"CHIEF MEDICAL OFFICER","shares":459,"price_per_share":51.5466,"usd_value":23660,"security_title":"Common Stock","importance":35.0236598894},{"ts":"2026-07-17","kind":"sec.insider.s","reporter":"Hohl Benjamin","title":"CHIEF FINANCIAL OFFICER","shares":369,"price_per_share":51.4823,"usd_value":18997,"security_title":"Common Stock","importance":35.0189969687},{"ts":"2026-07-17","kind":"sec.insider.s","reporter":"Hohl Benjamin","title":"CHIEF FINANCIAL OFFICER","shares":324,"price_per_share":49.9715,"usd_value":16191,"security_title":"Common Stock","importance":35.016190766},{"ts":"2026-07-17","kind":"sec.insider.s","reporter":"Collins Helen Louise","title":"CHIEF MEDICAL OFFICER","shares":231,"price_per_share":50.0542,"usd_value":11563,"security_title":"Common Stock","importance":35.0115625202},{"ts":"2026-07-17","kind":"sec.insider.s","reporter":"Hohl Benjamin","title":"CHIEF FINANCIAL OFFICER","shares":123,"price_per_share":53.8716,"usd_value":6626,"security_title":"Common Stock","importance":35.0066262068},{"ts":"2026-07-17","kind":"sec.insider.s","reporter":"Collins Helen Louise","title":"CHIEF MEDICAL OFFICER","shares":63,"price_per_share":53.9208,"usd_value":3397,"security_title":"Common Stock","importance":35.0033970104},{"ts":"2026-07-17","kind":"sec.filing","form_type":"144","title":"144 — Enliven Therapeutics, Inc. — 2026-07-17","url_slug":"/sec/cik-0001672619/144/0001974158-26-000084","accession_number":"0001974158-26-000084","importance":30},{"ts":"2026-07-17","kind":"sec.insider.m","reporter":"Collins Helen Louise","title":"CHIEF MEDICAL OFFICER","shares":5000,"price_per_share":2.48,"usd_value":12400,"security_title":"Common Stock","importance":15.0124},{"ts":"2026-07-17","kind":"sec.insider.m","reporter":"Hohl Benjamin","title":"CHIEF FINANCIAL OFFICER","shares":1072,"price_per_share":2.48,"usd_value":2659,"security_title":"Common Stock","importance":15.00265856},{"ts":"2026-07-06","kind":"sec.insider.s","reporter":"Kunkel Lori Anne","title":"","shares":5889,"price_per_share":50.8442,"usd_value":299421,"security_title":"Common Stock","importance":35.2994214938},{"ts":"2026-07-06","kind":"sec.insider.s","reporter":"Kunkel Lori Anne","title":"","shares":4111,"price_per_share":49.9834,"usd_value":205482,"security_title":"Common Stock","importance":35.2054817574},{"ts":"2026-06-24","kind":"sec.filing","form_type":"SCHEDULE 13D/A","title":"SCHEDULE 13D/A — ORBIMED ADVISORS LLC — 2026-06-24","url_slug":"/sec/cik-0001055951/schedule-13d-a/0000947871-26-000651","accession_number":"0000947871-26-000651","importance":70},{"ts":"2026-06-24","kind":"sec.filing","form_type":"4","title":"4 — ORBIMED ADVISORS LLC — 2026-06-24","url_slug":"/sec/cik-0001055951/4/0000947871-26-000653","accession_number":"0000947871-26-000653","importance":30},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"ORBIMED ADVISORS LLC","title":"","shares":787024,"price_per_share":45.38,"usd_value":35715149,"security_title":"Common Stock","importance":70.71514912},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"OrbiMed Capital GP VII LLC","title":"","shares":787024,"price_per_share":45.38,"usd_value":35715149,"security_title":"Common Stock","importance":70.71514912},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"OrbiMed Genesis GP LLC","title":"","shares":787024,"price_per_share":45.38,"usd_value":35715149,"security_title":"Common Stock","importance":70.71514912},{"ts":"2026-06-22","kind":"sec.form144","reporter":"OrbiMed Private Investments VII, LP","title":"Shareholder","shares":null,"usd_value":null,"security_title":null,"approx_sale_date":null,"accession_number":"0000947871-26-000649","importance":40},{"ts":"2026-06-22","kind":"sec.form144","reporter":"OrbiMed Genesis Master Fund, L.P.","title":"Shareholder","shares":null,"usd_value":null,"security_title":null,"approx_sale_date":null,"accession_number":"0000947871-26-000650","importance":40},{"ts":"2026-06-22","kind":"sec.form144","reporter":"The Biotech Growth Trust PLC","title":"Shareholder","shares":null,"usd_value":null,"security_title":null,"approx_sale_date":null,"accession_number":"0000947871-26-000648","importance":40},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"ORBIMED ADVISORS LLC","title":"","shares":46776,"price_per_share":45,"usd_value":2104920,"security_title":"Common Stock","importance":37.10492},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"OrbiMed Capital GP VII LLC","title":"","shares":46776,"price_per_share":45,"usd_value":2104920,"security_title":"Common Stock","importance":37.10492},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"OrbiMed Genesis GP LLC","title":"","shares":46776,"price_per_share":45,"usd_value":2104920,"security_title":"Common Stock","importance":37.10492},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"ORBIMED ADVISORS LLC","title":"","shares":24846,"price_per_share":45.38,"usd_value":1127511,"security_title":"Common Stock","importance":36.12751148},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"OrbiMed Capital GP VII LLC","title":"","shares":24846,"price_per_share":45.38,"usd_value":1127511,"security_title":"Common Stock","importance":36.12751148},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"OrbiMed Genesis GP LLC","title":"","shares":24846,"price_per_share":45.38,"usd_value":1127511,"security_title":"Common Stock","importance":36.12751148},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"ORBIMED ADVISORS LLC","title":"","shares":1477,"price_per_share":45,"usd_value":66465,"security_title":"Common Stock","importance":35.066465},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"OrbiMed Capital GP VII LLC","title":"","shares":1477,"price_per_share":45,"usd_value":66465,"security_title":"Common Stock","importance":35.066465},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"OrbiMed Genesis GP LLC","title":"","shares":1477,"price_per_share":45,"usd_value":66465,"security_title":"Common Stock","importance":35.066465},{"ts":"2026-06-22","kind":"sec.filing","form_type":"144","title":"144 — ORBIMED ADVISORS LLC — 2026-06-22","url_slug":"/sec/cik-0001055951/144/0000947871-26-000649","accession_number":"0000947871-26-000649","importance":30},{"ts":"2026-06-22","kind":"sec.filing","form_type":"144","title":"144 — ORBIMED ADVISORS LLC — 2026-06-22","url_slug":"/sec/cik-0001055951/144/0000947871-26-000650","accession_number":"0000947871-26-000650","importance":30},{"ts":"2026-06-22","kind":"sec.filing","form_type":"144","title":"144 — ORBIMED CAPITAL LLC — 2026-06-22","url_slug":"/sec/cik-0001157524/144/0000947871-26-000648","accession_number":"0000947871-26-000648","importance":30},{"ts":"2026-06-22","kind":"sec.filing","form_type":"4","title":"4 — Enliven Therapeutics, Inc. — 2026-06-22","url_slug":"/sec/cik-0001672619/4/0001701247-26-000010","accession_number":"0001701247-26-000010","importance":30},{"ts":"2026-06-22","kind":"sec.filing","form_type":"4","title":"4 — Enliven Therapeutics, Inc. — 2026-06-22","url_slug":"/sec/cik-0001672619/4/0001882764-26-000005","accession_number":"0001882764-26-000005","importance":30},{"ts":"2026-06-22","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Enliven Therapeutics, Inc. — 2026-06-22","url_slug":"/sec/cik-0001672619/schedule-13g-a/0001172661-26-002461","accession_number":"0001172661-26-002461","importance":30},{"ts":"2026-06-17","kind":"sec.form144","reporter":"Hohl Benjamin","title":"Officer","shares":18054,"usd_value":768198,"security_title":"Common","approx_sale_date":"2026-06-17","accession_number":"0001974158-26-000074","importance":40.15363954},{"ts":"2026-06-17","kind":"sec.insider.s","reporter":"Hohl Benjamin","title":"CHIEF FINANCIAL OFFICER","shares":3401,"price_per_share":43.8634,"usd_value":149179,"security_title":"Common Stock","importance":35.1491794234},{"ts":"2026-06-17","kind":"sec.insider.s","reporter":"Collins Helen Louise","title":"CHIEF MEDICAL OFFICER","shares":2599,"price_per_share":43.8701,"usd_value":114018,"security_title":"Common Stock","importance":35.1140183899},{"ts":"2026-06-17","kind":"sec.insider.s","reporter":"Hohl Benjamin","title":"CHIEF FINANCIAL OFFICER","shares":1379,"price_per_share":42.785,"usd_value":59001,"security_title":"Common Stock","importance":35.059000515},{"ts":"2026-06-17","kind":"sec.insider.s","reporter":"Hohl Benjamin","title":"CHIEF FINANCIAL OFFICER","shares":1238,"price_per_share":44.7475,"usd_value":55397,"security_title":"Common Stock","importance":35.055397405},{"ts":"2026-06-17","kind":"sec.insider.s","reporter":"Collins Helen Louise","title":"CHIEF MEDICAL OFFICER","shares":1268,"price_per_share":42.827,"usd_value":54305,"security_title":"Common Stock","importance":35.054304636},{"ts":"2026-06-17","kind":"sec.insider.s","reporter":"Collins Helen Louise","title":"CHIEF MEDICAL OFFICER","shares":1133,"price_per_share":44.743,"usd_value":50694,"security_title":"Common Stock","importance":35.050693819},{"ts":"2026-06-17","kind":"sec.filing","form_type":"144","title":"144 — Enliven Therapeutics, Inc. — 2026-06-17","url_slug":"/sec/cik-0001672619/144/0001974158-26-000074","accession_number":"0001974158-26-000074","importance":30},{"ts":"2026-06-17","kind":"sec.insider.m","reporter":"Hohl Benjamin","title":"CHIEF FINANCIAL OFFICER","shares":6018,"price_per_share":2.48,"usd_value":14925,"security_title":"Common Stock","importance":15.01492464},{"ts":"2026-06-17","kind":"sec.insider.m","reporter":"Collins Helen Louise","title":"CHIEF MEDICAL OFFICER","shares":5000,"price_per_share":2.48,"usd_value":12400,"security_title":"Common Stock","importance":15.0124},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"ORBIMED ADVISORS LLC","title":"","shares":272322,"price_per_share":45.02,"usd_value":12259936,"security_title":"Common Stock","importance":47.259936440000004},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"OrbiMed Capital GP VII LLC","title":"","shares":272322,"price_per_share":45.02,"usd_value":12259936,"security_title":"Common Stock","importance":47.259936440000004},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"OrbiMed Genesis GP LLC","title":"","shares":272322,"price_per_share":45.02,"usd_value":12259936,"security_title":"Common Stock","importance":47.259936440000004},{"ts":"2026-06-15","kind":"sec.form144","reporter":"OrbiMed Private Investments VII, LP","title":"Shareholder","shares":272322,"usd_value":11535560,"security_title":"Common Stock","approx_sale_date":"2026-06-15","accession_number":"0000947871-26-000628","importance":42.307111984},{"ts":"2026-06-15","kind":"sec.form144","reporter":"The Biotech Growth Trust PLC","title":"Shareholder","shares":10243,"usd_value":433893,"security_title":"Common Stock","approx_sale_date":"2026-06-15","accession_number":"0000947871-26-000629","importance":40.086778696},{"ts":"2026-06-15","kind":"sec.form144","reporter":"OrbiMed Genesis Master Fund, L.P.","title":"Shareholder","shares":9086,"usd_value":384883,"security_title":"Common Stock","approx_sale_date":"2026-06-15","accession_number":"0000947871-26-000627","importance":40.076976592},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"ORBIMED ADVISORS LLC","title":"","shares":9086,"price_per_share":45.02,"usd_value":409052,"security_title":"Common Stock","importance":35.40905172},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"OrbiMed Capital GP VII LLC","title":"","shares":9086,"price_per_share":45.02,"usd_value":409052,"security_title":"Common Stock","importance":35.40905172},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"OrbiMed Genesis GP LLC","title":"","shares":9086,"price_per_share":45.02,"usd_value":409052,"security_title":"Common Stock","importance":35.40905172},{"ts":"2026-06-12","kind":"sec.filing","form_type":"8-K","title":"8-K — Enliven Therapeutics, Inc. — 2026-06-12","url_slug":"/sec/cik-0001672619/8-k/0001193125-26-269635","accession_number":"0001193125-26-269635","importance":35},{"ts":"2026-06-12","kind":"sec.filing","form_type":"424B5","title":"424B5 — Enliven Therapeutics, Inc. — 2026-06-12","url_slug":"/sec/cik-0001672619/424b5/0001193125-26-269621","accession_number":"0001193125-26-269621","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"8-K","title":"8-K — Enliven Therapeutics, Inc. — 2026-06-11","url_slug":"/sec/cik-0001672619/8-k/0001193125-26-266731","accession_number":"0001193125-26-266731","importance":35},{"ts":"2026-06-11","kind":"sec.filing","form_type":"424B5","title":"424B5 — Enliven Therapeutics, Inc. — 2026-06-11","url_slug":"/sec/cik-0001672619/424b5/0001193125-26-267938","accession_number":"0001193125-26-267938","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"8-K","title":"8-K — Enliven Therapeutics, Inc. — 2026-06-10","url_slug":"/sec/cik-0001672619/8-k/0001193125-26-264085","accession_number":"0001193125-26-264085","importance":35},{"ts":"2026-06-05","kind":"sec.form144","reporter":"Kunkel Lori Anne","title":"Board Member","shares":20000,"usd_value":709800,"security_title":"Common","approx_sale_date":"2026-06-05","accession_number":"0001974158-26-000072","importance":40.14196},{"ts":"2026-06-05","kind":"sec.insider.s","reporter":"Kunkel Lori Anne","title":"","shares":7779,"price_per_share":34.2794,"usd_value":266659,"security_title":"Common Stock","importance":35.2666594526},{"ts":"2026-06-05","kind":"sec.insider.s","reporter":"Kunkel Lori Anne","title":"","shares":1867,"price_per_share":35.3573,"usd_value":66012,"security_title":"Common Stock","importance":35.0660120791},{"ts":"2026-06-05","kind":"sec.insider.s","reporter":"Kunkel Lori Anne","title":"","shares":354,"price_per_share":35.8187,"usd_value":12680,"security_title":"Common Stock","importance":35.0126798198},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Enliven Therapeutics, Inc. — 2026-05-20","url_slug":"/sec/cik-0001672619/4/0001701247-26-000007","accession_number":"0001701247-26-000007","importance":30},{"ts":"2026-05-18","kind":"sec.form144","reporter":"Collins Helen Louise","title":"Officer","shares":15000,"usd_value":620100,"security_title":"Common","approx_sale_date":"2026-05-18","accession_number":"0001974158-26-000069","importance":40.12402},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Collins Helen Louise","title":"CHIEF MEDICAL OFFICER","shares":3475,"price_per_share":39.534,"usd_value":137381,"security_title":"Common Stock","importance":35.13738065},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Collins Helen Louise","title":"CHIEF MEDICAL OFFICER","shares":1302,"price_per_share":40.2473,"usd_value":52402,"security_title":"Common Stock","importance":35.0524019846},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Collins Helen Louise","title":"CHIEF MEDICAL OFFICER","shares":223,"price_per_share":41.2052,"usd_value":9189,"security_title":"Common Stock","importance":35.0091887596},{"ts":"2026-05-18","kind":"sec.filing","form_type":"144","title":"144 — Enliven Therapeutics, Inc. — 2026-05-18","url_slug":"/sec/cik-0001672619/144/0001974158-26-000069","accession_number":"0001974158-26-000069","importance":30},{"ts":"2026-05-18","kind":"sec.insider.m","reporter":"Collins Helen Louise","title":"CHIEF MEDICAL OFFICER","shares":5000,"price_per_share":2.48,"usd_value":12400,"security_title":"Common Stock","importance":15.0124},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Enliven Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001672619/schedule-13g-a/0000902664-26-002551","accession_number":"0000902664-26-002551","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Enliven Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001672619/schedule-13g-a/0001104659-26-062642","accession_number":"0001104659-26-062642","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Enliven Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001672619/schedule-13g-a/0001172661-26-002051","accession_number":"0001172661-26-002051","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Enliven Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001672619/schedule-13g-a/0001172661-26-002402","accession_number":"0001172661-26-002402","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Enliven Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001672619/schedule-13g-a/0001738048-26-000062","accession_number":"0001738048-26-000062","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Enliven Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001672619/schedule-13g-a/0001831942-26-000024","accession_number":"0001831942-26-000024","importance":30},{"ts":"2026-04-27","kind":"sec.filing","form_type":"DEF 14A","title":"DEF 14A — Enliven Therapeutics, Inc. — 2026-04-27","url_slug":"/sec/cik-0001672619/def-14a/0001193125-26-182045","accession_number":"0001193125-26-182045","importance":40},{"ts":"2026-04-27","kind":"sec.filing","form_type":"ARS","title":"ARS — Enliven Therapeutics, Inc. — 2026-04-27","url_slug":"/sec/cik-0001672619/ars/0001193125-26-182102","accession_number":"0001193125-26-182102","importance":30},{"ts":"2026-04-27","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — Enliven Therapeutics, Inc. — 2026-04-27","url_slug":"/sec/cik-0001672619/defa14a/0001193125-26-182081","accession_number":"0001193125-26-182081","importance":30}]}